drugset
drugset / Trial / NCT02760316

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567.

NCT02760316 ↗

Phase 1 Completed 64 enrolled AstraZeneca
RandomizedParallel-groupSingle-blindTreatment

Summary

A study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of AZD9567.

Timeline

Start
2016-05-02
Primary completion
2017-09-11
Completion
2017-09-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject MIZACORAT Small molecule 10 mg Oral
Subject MIZACORAT Small molecule 20 mg Oral
Subject MIZACORAT Small molecule 40 mg Oral
Subject MIZACORAT Small molecule 80 mg Oral
Subject MIZACORAT Small molecule 125 mg Oral
Subject MIZACORAT Small molecule 155 mg Oral
Comparator Prednisolone Other / unclassified 5 mg Oral
Comparator Prednisolone Other / unclassified 20 mg Oral
Comparator Prednisolone Other / unclassified 40 mg Oral

Indications

rheumatoid arthritis